Telesis Bio Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
110
- Stock Symbol
-
TBIO
- Investments
-
1
- Share Price
-
$0.01
- (As of Thursday Closing)
Telesis Bio General Information
Description
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents and BioXp biofoundry services.
Contact Information
Website
www.telesisbio.comCorporate Office
- 10421 Wateridge Circle
- Suite 200
- San Diego, CA 92121-2993
- United States
Corporate Office
- 10421 Wateridge Circle
- Suite 200
- San Diego, CA 92121-2993
- United States
Telesis Bio Timeline
Telesis Bio Stock Performance
As of 12-Nov-2026, Telesis Bio’s stock price is $0.01. Its current market cap is $19.5K.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.01 | $0.01 | $19.5K | 1.22K |
Telesis Bio Financials Summary
As of 30-Jun-2024, Telesis Bio has a trailing 12-month revenue of $16.3M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 56,549 | 49,146 | 7,048 | 222,317 |
| Revenue | 16,280 | 27,509 | 27,435 | 11,043 |
| EBITDA | (42,428) | (42,236) | (44,355) | (36,001) |
| Net Income | (49,540) | (47,724) | (48,471) | (38,958) |
| Total Assets | 52,727 | 70,411 | 81,362 | 116,257 |
| Total Debt | 35,553 | 34,380 | 21,427 | 17,322 |
Telesis Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Telesis Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Telesis Bio Comparisons
Industry
Financing
Details
Telesis Bio Competitors (8)
One of Telesis Bio’s 8 competitors is Twist Bioscience, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| Integrated DNA Technologies | Formerly PE-Backed | Coralville, IA | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| Azenta Life Sciences | Corporation | Burlington, MA | ||||
| GenScript | Formerly VC-backed | Nanjing, China |
Telesis Bio Patents
Telesis Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025269170-A1 | Methods of synthesizing nucleic acid molecules | Pending | 09-May-2024 | ||
| US-20250346886-A1 | Methods of synthesizing nucleic acid molecules | Pending | 09-May-2024 | ||
| WO-2025235935-A1 | Methods of synthesizing nucleic acid molecules | Pending | 09-May-2024 | ||
| AU-2022485012-A1 | Methods of synthesizing nucleic acid molecules | Pending | 31-Oct-2022 | ||
| EP-4612311-A1 | Methods of synthesizing nucleic acid molecules | Pending | 31-Oct-2022 | C12P19/34 |
Telesis Bio Signals
Telesis Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Telesis Bio Acquisitions (1)
Telesis Bio’s most recent deal was a Merger/Acquisition with Eton BioScience for . The deal was made on 10-Nov-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eton BioScience | 10-Nov-2021 | Merger/Acquisition | Biotechnology |
Telesis Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Telesis Bio Exits (1)
Telesis Bio’s most recent exit was on 10-Nov-2021 from Eton BioScience. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Eton BioScience | 10-Nov-2021 | Completed |
|
Telesis Bio FAQs
-
When was Telesis Bio founded?
Telesis Bio was founded in 2011.
-
Where is Telesis Bio headquartered?
Telesis Bio is headquartered in San Diego, CA.
-
What is the size of Telesis Bio?
Telesis Bio has 110 total employees.
-
What industry is Telesis Bio in?
Telesis Bio’s primary industry is Discovery Tools (Healthcare).
-
Is Telesis Bio a private or public company?
Telesis Bio is a Public company.
-
What is Telesis Bio’s stock symbol?
The ticker symbol for Telesis Bio is TBIO.
-
What is the current stock price of Telesis Bio?
As of 12-Nov-2026 the stock price of Telesis Bio is $0.01.
-
What is the current market cap of Telesis Bio?
The current market capitalization of Telesis Bio is $19.5K.
-
What is Telesis Bio’s current revenue?
The trailing twelve month revenue for Telesis Bio is $16.3M.
-
Who are Telesis Bio’s competitors?
Twist Bioscience, Integrated DNA Technologies, Novus Biologicals, Azenta Life Sciences, and GenScript are some of the 8 competitors of Telesis Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process